

Global Biosimilars Market – Products, Applications and Regulations

<https://marketpublishers.com/r/G6CB7589805EN.html>

Date: January 2021

Pages: 356

Price: US\$ 4,050.00 (Single User License)

ID: G6CB7589805EN

Abstracts

Report Synopsis

Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies' commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. These new dynamics greatly change how companies should be building models of commercialization that also has vast implications for potential BD partnerships. The solution to 'build versus buy' is no longer driven by the size, scale, and cost of a sales force leading to outdated product P&L's. However, a hybrid solution that a partial build plus skilled, experienced contractors plus CSO for sales reps will be the optimal solution. This hybrid model could allow for greater biosimilar uptake and more efficient uptake.

Global market for Biosimilars is dominated by Oncology, estimated at US\$5.4 billion (38.6% share) in 2020, which is anticipated to post the slowest CAGR of 29% between 2020 and 2026 and reach a projected US\$24.8 billion by 2026.

Research Findings & Coverage

Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas

The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally

mAbs - All the Rage in Biosimilars' New Wave

Patent Expirations of Major Biologics Leads Way for Biosimilars

Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation

Availability of Biosimilar May Affect Biologic Drug Pricing

Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments

Major companies profiled – 36

The industry guide includes the contact details for 155 companies

Product Outline

The report analyzes the market for the following key product types of Biosimilars:

Monoclonal Antibodies (mAB)

Erythropoietin (EPO)

Granulocyte Colony-Stimulating Factor (G-CSF)

Insulin

Others (includes Interferons, Follitropins, Recombinant Proteins etc.)

Therapeutic areas of Biosimilars analyzed in this study comprise the following:

Oncology

Autoimmune Disorders

Blood Disorders

Growth Hormone Deficiency

Others (includes Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)

Analysis Period, Units and Growth Rates

The report reviews, analyzes and projects the global Biosimilars market for the period 2017-2026 in terms of US\$ and the compound annual growth rates (CAGRs) projected from 2019 through 2026

Geographic Coverage

North America (The United States, Canada and Mexico)

Europe (Germany, the United Kingdom, France, Spain, Italy and Rest of Europe)

Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)

Rest of World (Brazil, Israel and Other Rest of World)

Contents

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 Product Outline

1.1.1 Biosimilars Defined

1.1.2 Backdrop

1.1.3 The Biologics Price Competition and Innovation Act (BPCI Act)

1.1.3.1 Data Exclusivity

1.1.4 Steps Involved in Biosimilar Synthesis

1.1.5 Key Regulatory Authorization Pathway – Synopsis

1.1.6 Biosimilars Types

1.1.6.1 Monoclonal Antibodies (mAB or moAB)

1.1.6.1.1 Production Process

1.1.6.1.1.1 Hybridoma Cell Production

1.1.6.1.2 Therapeutic Applications

1.1.6.2 Erythropoietin (EPO)

1.1.6.2.1 Functions of EPO

1.1.6.2.2 Mechanism of Action

1.1.6.2.3 Synthesis and Regulation

1.1.6.2.4 Uses in Medicine

1.1.6.3 Granulocyte Colony-Stimulating Factor (G-CSF)

1.1.6.3.1 Biological Function

1.1.6.3.2 Genetics

1.1.6.3.3 Use in Therapeutics

1.1.6.4 Insulin

1.1.6.4.1 Biosimilar Insulin

1.1.6.4.2 The Complexity in Producing Biosimilar Insulin

1.1.6.4.3 Biosimilar Insulins and the Regulatory Environment Surrounding Them

1.1.6.4.4 The Market for Biosimilar Insulins

1.1.6.5 Interferons

1.1.6.5.1 Interferon Categorization

1.1.6.5.2 Functions of Interferons

1.1.6.5.3 Interferon Alfa

1.1.6.5.4 Interferon Beta-1a

1.1.6.5.5 Interferon Gamma

1.1.6.6 Human Growth Hormone

1.1.6.6.1 Recombinant Human Growth Hormone

1.1.6.6.2 Managing Growth Disorders Using Recombinant Human Growth Hormone

Biosimilars

1.1.6.7 Other Biosimilars

1.1.7 Biosimilars Therapeutic Areas

1.1.7.1 Oncology

1.1.7.1.1 Biosimilar G-CSF

1.1.7.2 Autoimmune Diseases

1.1.7.3 Blood Disorders

1.1.7.4 Growth Hormone Deficiency (GHD)

1.1.7.4.1 Growth Hormone Deficiency in Children

1.1.7.5 Infectious Diseases

1.1.7.5.1 Treatment of Infectious Diseases

2. REGULATORY LANDSCAPE

2.1 The United States

2.1.1 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product

2.1.2 Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product

2.1.3 Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

2.1.4 FDA Issues New Regulatory Updates in 2020

2.2 European

2.3 The World Health Organization (WHO)

2.4 Canada

2.5 South Korea

2.6 China

2.7 India

2.8 Japan

2.9 Mexico

2.10 Brazil

2.11 Argentina

3. KEY MARKET TRENDS

3.1 mAbs - All The Rage In Biosimilars' New Wave

3.1.1 The Buildup to the Biosimilar Industry

3.1.2 Biosimilars of mAbs Approved: A Sneak Preview

3.2 Patent Expirations of Major Biologics Leads Way for Biosimilars

3.3 Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation

3.4 Availability of Biosimilar May Affect Biologic Drug Pricing

3.5 Asia-Pacific Witnessing a Boom of Biosimilars

4. RECENT BIOSIMILARS APPROVALS

5. KEY GLOBAL PLAYERS

Amgen Inc. (The United States)
AXXO GmbH (Germany)
BIOCAD (Russia)
Biogen, Inc. (The United States)
Bioton S.A. (Poland)
C.H. Boehringer Sohn AG & Co., KG. (Germany)
Coherus Biosciences (The United States)
Creative BioMart (The United States)
Dong-A Socio Group (South Korea)
Dr. Reddy's Laboratories Ltd. (India)
Eli Lilly and Company (The United States)
Genor Biopharma Co., Ltd. (China)
Hetero Drugs Limited (India)
Insud Pharma SL (Spain)
mAbxience SA (Spain)
Intas Pharmaceuticals Ltd. (India)
Kashiv Biosciences LLC (The United States)
LG Chem (South Korea)
Lupin Limited (India)
Mylan, Inc (The United States)
Nippon Kayaku Co., Ltd. (Japan)
Pfizer, Inc. (The United States)
Reliance Life Sciences Pvt. Ltd. (India)
Sandoz International GmbH (Germany)
Shanghai Henlius Biotech, Inc. (China)
STADA Arzneimittel AG (Germany)
Teva Pharmaceutical Industries Limited (Israel)
Wockhardt Limited (India)

6. KEY BUSINESS AND PRODUCT TRENDS

AbbVie Inc and Frontier Collaborate on Novel Therapies and E3 Degraders
Eli Lilly and UHG Collaborate on Bamlanivimab (LY-CoV555) Antibody Study
Merck Receives FDA Review Acceptance for KEYTRUDA® (pembrolizumab) Plus Chemotherapy
Samsung Bioepis and Biogen File U.S FDA Acceptance of SB11 Biosimilar
EMA Approves Roche's Xofluza® Biosimilar
Genor's New Drug Application for GB242 Infliximab Biosimilar is Under Review by NMPA
NeuClone Discloses it's Stelara® Biosimilar Candidate Clinical Trials
FDA Approval for Anti-IL-4R? Monoclonal Antibody
Pfizer's NYVEPRIA™ Biosimilar Receives FDA Approval
Biocon Ltd Establishes Biosimilar Plant in India
Boehringer Acquires Northern Biologics, Inc
Biocon Ltd. and Mylan N.V Unveils Fulphila® Biosimilar
mAbxience Establishes New Biosimilar Antibody Plant in Argentina
CHMP Recommends RUXIENCE™ Biosimilar
FDA Approval for ABP 798, a Biosimilar Candidate to Rituxan®
Amgen Receives FDA Approval for its AVSOLA™ (Infliximab-axxq) Biosimilar Antibody
3SBio, Inc and Verseau Agree on Monoclonal Antibody Development - VTX-0811
Boehringer Ingelheim Discloses GioTag Study Results
Dr. Reddy's Lab Unveils Versavo® Biosimilar
Allergan and Gedeon Receive FDA Approval for VRAYLAR® Drug Use
Samsung Bioepis Signs Biosimilars Development and Marketing Agreement with C-Bridge Capital
Biosimilar Association of Samsung Bioepis and 3SBio
Kashiv Pharma Renamed as KashivBioSciences Post Acquiring Adello Biologics
Intas Unveils New Pegylated G-CSF Biosimilar in Europe
Japanese Release of Trastuzumab and Agalsidase Beta Biosimilar
Epoetin Alfa and Pegfilgrastim Biosimilars Now Accessible In the US at Considerable Concession
Biosimilars of Insulin Glargine Introduced in South Korea and the UK
CNDA Accepted Review of Adalimumab Biosimilar
Filgrastim Biosimilar Application Submitted to the US FDA
European Commercial Release of Amgevita and Imraldi
MHLW of Japan Received Approval Application for Dual Darbepoetin Alfa Copy Biologics
Evaluation of Adalimumab Biosimilar SB5 by USFDA
Acceptance of Approval Application by CFDA for Adalimumab Biosimilar

Review Acceptance for MabionCD20 by EMA and Rituxan Expanded the Therapeutic Range

Dr Reddy's Introduces Hervycta, A Trastuzumab Biosimilar in India

Apotex Influence Canadian Biosimilar Market

Resubmission of Marketing Approval of Biosimilar Rituximab to FDA by Celltrion

Refusal of Trastuzumab and Rituximab Biosimilars Approval Applications by FDA

Rejection of Rituximab and Trastuzumab of Celltrion/Teva by FDA

Amgen and Allergan Authorize ABP 980 Biosimilar

OntruzantTrastuzumab Biosimilar Released in the UK

Commercialization of Trastuzumab Biosimilar in South Korea By Daewoong

Commercial Release of Adalimumab Biosimilar in India by Hetero

Production of Denosumab Biosimilar in Australia

7. GLOBAL MARKET OVERVIEW

7.1 Global Biosimilars Market Overview by Product Type

7.1.1 Global Biosimilars Product Types Market Overview by Geographic Region

7.1.1.1 Monoclonal Antibodies

7.1.1.2 Erythropoietin

7.1.1.3 G-CSF

7.1.1.4 Insulin

7.1.1.5 Other Product Types

7.2 Global Biosimilars Market Overview by Therapeutic Area

7.2.1 Global Biosimilars Therapeutic Area Market Overview by Geographic Region

7.2.1.1 Oncology

7.2.1.2 Autoimmune Disorders

7.2.1.3 Blood Disorders

7.2.1.4 Growth Hormone Deficiency

7.2.1.5 Other Therapeutic Areas

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

8. EUROPE

8.1 European Biosimilars Market Overview by Geographic Region

8.2 European Biosimilars Market Overview by Product Type

8.2.1 European Biosimilars Product Types Market Overview by Geographic Region

8.2.1.1 Monoclonal Antibodies

8.2.1.2 Erythropoietin

8.2.1.3 G-CSF

8.2.1.4 Insulin

8.2.1.5 Other Product Types

8.3 European Biosimilars Market Overview by Therapeutic Area

8.3.1 European Biosimilars Therapeutic Area Market Overview by Geographic Region

8.3.1.1 Oncology

8.3.1.2 Autoimmune Disorders

8.3.1.3 Blood Disorders

8.3.1.4 Growth Hormone Deficiency

8.3.1.5 Other Therapeutic Areas

8.4 Major Market Players

AXXO GmbH (Germany)

BIOCAD (Russia)

Bioton S.A. (Poland)

C.H. Boehringer Sohn AG & Co., KG. (Germany)

F. Hoffmann-La Roche Ltd (Switzerland)

Fresenius Kabi AG (Germany)

Insud Pharma SL (Spain)

mAbxience SA (Spain)

Sandoz International GmbH (Germany)

STADA Arzneimittel AG (Germany)

8.5 Country-wise analysis of European Biosimilars Market

8.5.1 Germany

8.5.1.1 German Biosimilars Market Overview by Product Type

8.5.1.2 German Biosimilars Market Overview by Therapeutic Area

8.5.2 United Kingdom

8.5.2.1 United Kingdom Biosimilars Market Overview by Product Type

8.5.2.2 United Kingdom Biosimilars Market Overview by Therapeutic Area

8.5.3 France

8.5.3.1 French Biosimilars Market Overview by Product Type

8.5.3.2 French Biosimilars Market Overview by Therapeutic Area

8.5.4 Spain

8.5.4.1 Spanish Biosimilars Market Overview by Product Type

8.5.4.2 Spanish Biosimilars Market Overview by Therapeutic Area

8.5.5 Italy

8.5.5.1 Italian Biosimilars Market Overview by Product Type

8.5.5.2 Italian Biosimilars Market Overview by Therapeutic Area

8.5.6 Rest of Europe

8.5.6.1 Rest of Europe Biosimilars Market Overview by Product Type

8.5.6.2 Rest of Europe Biosimilars Market Overview by Therapeutic Area

9. NORTH AMERICA

9.1 North American Biosimilars Market Overview by Geographic Region

9.2 North American Biosimilars Market Overview by Product Type

9.2.1 North American Biosimilars Product Types Market Overview by Geographic Region

9.2.1.1 Monoclonal Antibodies

9.2.1.2 Erythropoietin

9.2.1.3 G-CSF

9.2.1.4 Insulin

9.2.1.5 Other Product Types

9.3 North American Biosimilars Market Overview by Therapeutic Area

9.3.1 North American Biosimilars Therapeutic Area Market Overview by Geographic Region

9.3.1.1 Oncology

9.3.1.2 Autoimmune Disorders

9.3.1.3 Blood Disorders

9.3.1.4 Growth Hormone Deficiency

9.3.1.5 Other Therapeutic Areas

9.4 Major Market Players

Amgen Inc. (The United States)

Apotex, Inc. (Canada)

Biogen, Inc. (The United States)

Coherus BioSciences (The United States)

Creative Biomart, Inc. (The United States)

Eli Lilly and Company (The United States)

Kashiv Biosciences LLC (The United States)

Mylan, Inc (The United States)

Pfizer, Inc. (The United States)

Probiomed S.A. De C.V (Mexico)

9.5 Country-wise Analysis of North American Biosimilars Market

9.5.1 The United States

9.5.1.1 United States Biosimilars Market Overview by Product Type

9.5.1.2 United States Biosimilars Market Overview by Therapeutic Area

9.5.2 Canada

- 9.5.2.1 Canadian Biosimilars Market Overview by Product Type
- 9.5.2.2 Canadian Biosimilars Market Overview by Therapeutic Area
- 9.5.3 Mexico
 - 9.5.3.1 Mexican Biosimilars Market Overview by Product Type
 - 9.5.3.2 Mexican Biosimilars Market Overview by Therapeutic Area

10. ASIA-PACIFIC

- 10.1 Asia-Pacific Biosimilars Market Overview by Geographic Region
- 10.2 Asia-Pacific Biosimilars Market Overview by Product Type
 - 10.2.1 Asia-Pacific Biosimilars Product Types Market Overview by Geographic Region
 - 10.2.1.1 Monoclonal Antibodies
 - 10.2.1.2 Erythropoietin
 - 10.2.1.3 G-CSF
 - 10.2.1.4 Insulin
 - 10.2.1.5 Other Product Types
- 10.3 Asia-Pacific Biosimilars Market Overview by Therapeutic Area
 - 10.3.1 Asia-Pacific Biosimilars Therapeutic Area Market Overview by Geographic Region
 - 10.3.1.1 Oncology
 - 10.3.1.2 Autoimmune Disorders
 - 10.3.1.3 Blood Disorders
 - 10.3.1.4 Growth Hormone Deficiency
 - 10.3.1.5 Other Therapeutic Areas
- 10.4 Major Market Players
 - Celltrion, Inc. (South Korea)
 - Dong-A Socio Group (South Korea)
 - Dr. Reddy's Laboratories Ltd. (India)
 - Genor Biopharma Co., Ltd. (China)
 - Hetero Drugs Limited (India)
 - Intas Pharmaceuticals Ltd (India)
 - LG Chem (South Korea)
 - Lupin Limited (India)
 - Nippon Kayaku Co., Ltd. (Japan)
 - Reliance Life Sciences Pvt., Ltd. (India)
 - Samsung Biologics Co., Ltd. (South Korea)
 - Shanghai Henlius Biotech, Inc. (China)
 - Wockhardt Limited (India)
 - Zydus Cadila (India)

10.5 Country-wise Analysis of Asia-Pacific Biosimilars Market

10.5.1 China

10.5.1.1 Chinese Biosimilars Market Overview by Product Type

10.5.1.2 Chinese Biosimilars Market Overview by Therapeutic Area

10.5.2 India

10.5.2.1 Indian Biosimilars Market Overview by Product Type

10.5.2.2 Indian Biosimilars Market Overview by Therapeutic Area

10.5.3 Japan

10.5.3.1 Japanese Biosimilars Market Overview by Product Type

10.5.3.2 Japanese Biosimilars Market Overview by Therapeutic Area

10.5.4 South Korea

10.5.4.1 South Korean Biosimilars Market Overview by Product Type

10.5.4.2 South Korean Biosimilars Market Overview by Therapeutic Area

10.5.5 Rest of Asia-Pacific

10.5.5.1 Rest of Asia-Pacific Biosimilars Market Overview by Product Type

10.5.5.2 Rest of Asia-Pacific Biosimilars Market Overview by Therapeutic Area

11. REST OF WORLD

11.1 Rest of World Biosimilars Market Overview by Geographic Region

11.2 Rest of World Biosimilars Market Overview by Product Type

11.2.1 Rest of World Biosimilars Product Types Market Overview by Geographic Region

11.2.1.1 Monoclonal Antibodies

11.2.1.2 Erythropoietin

11.2.1.3 G-CSF

11.2.1.4 Insulin

11.2.1.5 Other Product Types

11.3 Rest of World Biosimilars Market Overview by Therapeutic Area

11.3.1 Rest of World Biosimilars Therapeutic Area Market Overview by Geographic Region

11.3.1.1 Oncology

11.3.1.2 Autoimmune Disorders

11.3.1.3 Blood Disorders

11.3.1.4 Growth Hormone Deficiency

11.3.1.5 Other Therapeutic Areas

11.4 Major Market Players

AMEGA Biotech (Argentina)

Teva Pharmaceutical Industries Limited (Israel)

11.5 Country-wise Analysis of Rest of World Biosimilars Market

11.5.1 Brazil

11.5.1.1 Brazilian Biosimilars Market Overview by Product Type

11.5.1.2 Brazilian Biosimilars Market Overview by Therapeutic Area

11.5.2 Israel

11.5.2.1 Israeli Biosimilars Market Overview by Product Type

11.5.2.2 Israeli Biosimilars Market Overview by Therapeutic Area

11.5.3 Other Countries

11.5.3.1 Other Countries Biosimilars Market Overview by Product Type

11.5.3.2 Other Countries Biosimilars Market Overview by Therapeutic Area

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA

2. EUROPE

3. ASIA-PACIFIC

4. REST OF WORLD

PART D: ANNEXURE

1. RESEARCH METHODOLOGY

2. FEEDBACK

List Of Charts

LIST OF CHARTS

PART A: GLOBAL MARKET PERSPECTIVE

Chart 1: Global Biosimilars Market (2020 & 2026) by Geographic Region

Chart 2: Global Biosimilars Market (2020 & 2026) by Product Type

Chart 3: Global Biosimilars Market (2020 & 2026) by Therapeutic Areas

Chart 4: Global Biosimilars Market Analysis (2017-2026) in USD Million

Chart 5: Global Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 6: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 7: Global Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in USD Million

Chart 8: Glance at 2017, 2020 and 2026 Global Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 9: Global Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 10: Glance at 2017, 2020 and 2026 Global Biosimilar Erythropoietin Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 11: Global Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 12: Glance at 2017, 2020 and 2026 Global Biosimilar G-CSF Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 13: Global Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 14: Glance at 2017, 2020 and 2026 Global Biosimilar Insulin Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 15: Global Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 16: Glance at 2017, 2020 and 2026 Global Other Biosimilar Products Types Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 17: Global Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and

Other in USD Million

Chart 18: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Chart 19: Global Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 20: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Oncology by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 21: Global Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 22: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 23: Global Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 24: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 25: Global Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 26: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

Chart 27: Global Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US\$ Million

Chart 28: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

Chart 29: Global Biosimilars Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in USD Million

Chart 30: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

REGIONAL MARKET OVERVIEW

EUROPE

Chart 31: European Biosimilars Market Analysis (2017-2026) in USD Million

Chart 32: European Biosimilars Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in USD Million

Chart 33: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 34: European Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 35: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 36: European Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in USD Million

Chart 37: Glance at 2017, 2020 and 2026 European Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 38: European Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 39: Glance at 2017, 2020 and 2026 European Biosimilar Erythropoietin Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 40: European Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 41: Glance at 2017, 2020 and 2026 European Biosimilar G-CSF Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 42: European Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 43: Glance at 2017, 2020 and 2026 European Biosimilar Insulin Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 44: European Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 45: Glance at 2017, 2020 and 2026 European Other Biosimilar Products Types

Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 46: European Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 47: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Chart 48: European Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 49: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Oncology by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 50: European Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 51: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 52: European Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 53: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 54: European Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 55: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Chart 56: European Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US\$ Million

Chart 57: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Germany

Chart 58: German Biosimilars Market Analysis (2017-2026) in USD Million

Chart 59: German Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 60: Glance at 2017, 2020 and 2026 German Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 61: German Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 62: Glance at 2017, 2020 and 2026 German Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

United Kingdom

Chart 63: United Kingdom Biosimilars Market Analysis (2017-2026) in USD Million

Chart 64: United Kingdom Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 65: Glance at 2017, 2020 and 2026 United Kingdom Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 66: United Kingdom Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 67: Glance at 2017, 2020 and 2026 United Kingdom Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

France

Chart 68: French Biosimilars Market Analysis (2017-2026) in USD Million

Chart 69: French Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 70: Glance at 2017, 2020 and 2026 French Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 71: French Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 72: Glance at 2017, 2020 and 2026 French Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Spain

Chart 73: Spanish Biosimilars Market Analysis (2017-2026) in USD Million

Chart 74: Spanish Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 75: Glance at 2017, 2020 and 2026 Spanish Biosimilars Market Share (%) by

Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 76: Spanish Biosimilars Market Analysis (2017-2026) by Therapeutic Area -

Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 77: Glance at 2017, 2020 and 2026 Spanish Biosimilars Market Share (%) by

Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Italy

Chart 78: Italian Biosimilars Market Analysis (2017-2026) in USD Million

Chart 79: Italian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 80: Glance at 2017, 2020 and 2026 Italian Biosimilars Market Share (%) by

Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 81: Italian Biosimilars Market Analysis (2017-2026) by Therapeutic Area -

Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 82: Glance at 2017, 2020 and 2026 Italian Biosimilars Market Share (%) by

Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Rest of Europe

Chart 83: Rest of Europe Biosimilars Market Analysis (2017-2026) in USD Million

Chart 84: Rest of Europe Biosimilars Market Analysis (2017-2026) by Product Type -

Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 85: Glance at 2017, 2020 and 2026 Rest of Europe Biosimilars Market Share (%)

by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 86: Rest of Europe Biosimilars Market Analysis (2017-2026) by Therapeutic Area

- Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 87: Glance at 2017, 2020 and 2026 Rest of Europe Biosimilars Market Share (%)

by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

NORTH AMERICA

Chart 88: North American Biosimilars Market Analysis (2017-2026) in USD Million

Chart 89: North American Biosimilars Market Analysis (2017-2026) by Geographic

Region - United States, Canada and Mexico in USD Million

Chart 90: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%)

by Geographic Region - United States, Canada and Mexico

Chart 91: North American Biosimilars Market Analysis (2017-2026) by Product Type -

Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 92: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 93: North American Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in USD Million

Chart 94: Glance at 2017, 2020 and 2026 North American Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - United States, Canada and Mexico

Chart 95: North American Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 96: Glance at 2017, 2020 and 2026 North American Biosimilar Erythropoietin Market Share (%) by Geographic Region - United States, Canada and Mexico

Chart 97: North American Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 98: Glance at 2017, 2020 and 2026 North American Biosimilar G-CSF Market Share (%) by Geographic Region - United States, Canada and Mexico

Chart 99: North American Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 100: Glance at 2017, 2020 and 2026 North American Biosimilar Insulin Market Share (%) by Geographic Region - United States, Canada and Mexico

Chart 101: North American Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 102: Glance at 2017, 2020 and 2026 North American Other Biosimilar Products Types Market Share (%) by Geographic Region - United States, Canada and Mexico

Chart 103: North American Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 104: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Chart 105: North American Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 106: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Oncology by Geographic Region - United States, Canada and Mexico

Chart 107: North American Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 108: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - United States, Canada and Mexico

Chart 109: North American Biosimilars Market Analysis (2017-2026) in Blood Disorders

by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 110: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Blood Disorders by Geographic Region - United States, Canada and Mexico

Chart 111: North American Biosimilars Market Analysis (2017-2026) in Growth

Hormone Deficiency by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 112: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - United States, Canada and Mexico

Chart 113: North American Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - United States, Canada and Mexico in US\$ Million

Chart 114: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - United States, Canada and Mexico

The United States

Chart 115: United States Biosimilars Market Analysis (2017-2026) in USD Million

Chart 116: United States Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 117: Glance at 2017, 2020 and 2026 United States Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 118: United States Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 119: Glance at 2017, 2020 and 2026 United States Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Canada

Chart 120: Canadian Biosimilars Market Analysis (2017-2026) in USD Million

Chart 121: Canadian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 122: Glance at 2017, 2020 and 2026 Canadian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 123: Canadian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 124: Glance at 2017, 2020 and 2026 Canadian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Mexico

Chart 125: Mexican Biosimilars Market Analysis (2017-2026) in USD Million

Chart 126: Mexican Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 127: Glance at 2017, 2020 and 2026 Mexican Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 128: Mexican Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 129: Glance at 2017, 2020 and 2026 Mexican Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

ASIA-PACIFIC

Chart 130: Asia-Pacific Biosimilars Market Analysis (2017-2026) in USD Million

Chart 131: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in USD Million

Chart 132: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 133: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 134: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 135: Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in USD Million

Chart 136: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 137: Asia-Pacific Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 138: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Erythropoietin Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 139: Asia-Pacific Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 140: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar G-CSF Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 141: Asia-Pacific Biosimilar Insulin Market Analysis (2017-2026) by Geographic

Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 142: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Insulin Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 143: Asia-Pacific Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 144: Glance at 2017, 2020 and 2026 Asia-Pacific Other Biosimilar Products Types Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 145: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 146: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Chart 147: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 148: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Oncology by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 149: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 150: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 151: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 152: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Blood Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 153: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 154: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

Chart 155: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US\$ Million

Chart 156: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

China

Chart 157: Chinese Biosimilars Market Analysis (2017-2026) in USD Million

Chart 158: Chinese Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 159: Glance at 2017, 2020 and 2026 Chinese Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 160: Chinese Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 161: Glance at 2017, 2020 and 2026 Chinese Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

India

Chart 162: Indian Biosimilars Market Analysis (2017-2026) in USD Million

Chart 163: Indian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 164: Glance at 2017, 2020 and 2026 Indian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 165: Indian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 166: Glance at 2017, 2020 and 2026 Indian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Japan

Chart 167: Japanese Biosimilars Market Analysis (2017-2026) in USD Million

Chart 168: Japanese Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 169: Glance at 2017, 2020 and 2026 Japanese Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 170: Japanese Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 171: Glance at 2017, 2020 and 2026 Japanese Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

South Korea

Chart 172: South Korean Biosimilars Market Analysis (2017-2026) in USD Million

Chart 173: South Korean Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 174: Glance at 2017, 2020 and 2026 South Korean Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 175: South Korean Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 176: Glance at 2017, 2020 and 2026 South Korean Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Rest of Asia-Pacific

Chart 177: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) in USD Million

Chart 178: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 179: Glance at 2017, 2020 and 2026 Rest of Asia-Pacific Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 180: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 181: Glance at 2017, 2020 and 2026 Rest of Asia-Pacific Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

REST OF WORLD

Chart 182: Rest of World Biosimilars Market Analysis (2017-2026) in USD Million

Chart 183: Rest of World Biosimilars Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in USD Million

Chart 184: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Geographic Region - Brazil, Israel and Other Countries

Chart 185: Rest of World Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 186: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 187: Rest of World Biosimilar Monoclonal Antibodies Market Analysis

(2017-2026) by Geographic Region - Brazil, Israel and Other Countries in USD Million

Chart 188: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Monoclonal

Antibodies Market Share (%) by Geographic Region - Brazil, Israel and Other Countries

Chart 189: Rest of World Biosimilar Erythropoietin Market Analysis (2017-2026) by

Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 190: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Erythropoietin

Market Share (%) by Geographic Region - Brazil, Israel and Other Countries

Chart 191: Rest of World Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 192: Glance at 2017, 2020 and 2026 Rest of World Biosimilar G-CSF Market Share (%) by Geographic Region - Brazil, Israel and Other Countries

Chart 193: Rest of World Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 194: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Insulin Market Share (%) by Geographic Region - Brazil, Israel and Other Countries

Chart 195: Rest of World Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 196: Glance at 2017, 2020 and 2026 Rest of World Other Biosimilar Products Types Market Share (%) by Geographic Region - Brazil, Israel and Other Countries

Chart 197: Rest of World Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 198: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Chart 199: Rest of World Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 200: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Oncology by Geographic Region - Brazil, Israel and Other Countries

Chart 201: Rest of World Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 202: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Brazil, Israel and Other Countries

Chart 203: Rest of World Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 204: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Brazil, Israel and Other Countries

Chart 205: Rest of World Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 206: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Brazil, Israel and Other Countries

Chart 207: Rest of World Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Brazil, Israel and Other Countries in US\$ Million

Chart 208: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Brazil, Israel and Other Countries
Brazil

Chart 209: Brazilian Biosimilars Market Analysis (2017-2026) in USD Million

Chart 210: Brazilian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 211: Glance at 2017, 2020 and 2026 Brazilian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 212: Brazilian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 213: Glance at 2017, 2020 and 2026 Brazilian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Israel

Chart 214: Israeli Biosimilars Market Analysis (2017-2026) in USD Million

Chart 215: Israeli Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 216: Glance at 2017, 2020 and 2026 Israeli Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 217: Israeli Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million

Chart 218: Glance at 2017, 2020 and 2026 Israeli Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Other Countries

Chart 219: Other Countries Biosimilars Market Analysis (2017-2026) in USD Million

Chart 220: Other Countries Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million

Chart 221: Glance at 2017, 2020 and 2026 Other Countries Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other

Chart 222: Other Countries Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency

and Other in USD Million

Chart 223: Glance at 2017, 2020 and 2026 Other Countries Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

List Of Tables

LIST OF TABLES

Table 1: Biosimilar Synonyms

Table 2: Comparison of Generics and Biosimilars

Table 3: List of the US and European Approved Biosimilars for Diabetes

Table 4: List of the US and European Approved Biosimilars for Oncology

Table 5: List of the US and European Approved Biosimilars for Autoimmune Disorders

Table 6: List of the US and European Approved Biosimilars for Blood Disorders

Table 7: List of the US and European Approved Biosimilars for Other Indications

Table 8: List of Leading Biologics Containing mAbs, Year of Approval and Patent Expiry in Europe and the United States

Table 9: Global Biosimilar Approvals Since 2006: mAbs Occupy Major Share

Table 10: Biosimilars Pipeline by Company

Table 11: Biosimilars Approvals from 2018 to 2020

I would like to order

Product name: Global Biosimilars Market – Products, Applications and Regulations

Product link: <https://marketpublishers.com/r/G6CB7589805EN.html>

Price: US\$ 4,050.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6CB7589805EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970